Rotarix and RotaTeq are highly effective in preventing severe rotavirus gastroenteritis, with ongoing monitoring required for rare adverse events like intussusception.
Answers are grounded in this paper and cite their sources.
Supports sustained rotavirus vaccination programs; leaves open needs for ongoing adverse-event surveillance in new populations.
Since the presentation of the clinical trial reports showing the excellent efficacy and safety of the two human rotavirus vaccines (Rotarix and RotaTeq), the human rotavirus vaccines have received worldwide attention. The two vaccines have been approved in more than 100 countries, and were included in routine immunization schedule in about 30 countries. The effectiveness of the two vaccines exceeded our expectations, and severe rotavirus gastroenteritis cases have been greatly reduced. Also in Japan, administration of Rotarix started just last November, and RotaTeq will be also started soon. On this occasion, composition, characteristics, and effectiveness of these vaccines are described, and some points relating to the vaccination such as intussusception, cross protection, shedding and so on are also discussed.
No takes yet. Share an insight, caveat, or question.
Koki Taniguchi (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: